Multi‐target angiogenesis inhibitor combined with <scp>PD</scp>‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of <scp>EGFR‐TKI</scp> therapy

Lian Yu(Shanghai Jiao Tong University), Runbo Zhong(Shanghai Jiao Tong University), Jinjing Xia(Shanghai Jiao Tong University), Rong Qiao(Shanghai Jiao Tong University), Hua Zhong(Shanghai Jiao Tong University), Jianlin Xu(Shanghai University), Yaohua Hu(Shanghai Aerospace Automobile Electromechanical (China)), Baohui Han(Shanghai Jiao Tong University)
International Journal of Cancer
April 20, 2023
10.1002/ijc.34536
Cited by 25

Related Papers

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
Consensus for HER2 alterations testing in non-small-cell lung cancer
|ESMO Open|2022|110
Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan
|Breast Cancer Research and Treatment|1997|93
Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease
|Cell Death and Disease|2013|88
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
|Lung Cancer|2014|51